Table 6. Basic information between adjuvant chemotherapy and ALK-TKI in pathologically nodal positive resectable ALK-rearranged NSCLC patients.
| Characteristics | Chemotherapy (n=136) | ALK-TKI (n=11) | P |
|---|---|---|---|
| Age, years | 52.9±9.9 | 62.3±11.5 | 0.023 |
| Gender | 0.808 | ||
| Male | 69 (50.7) | 6 (54.5) | |
| Female | 67 (49.3) | 5 (45.5) | |
| Smoking history | 0.698 | ||
| Current or ever | 24 (17.6) | 3 (27.3) | |
| Never | 112 (82.4) | 8 (72.7) | |
| ECOG PS | 0.747 | ||
| 0 | 111 (81.6) | 8 (72.7) | |
| 1–2 | 25 (18.4) | 3 (27.3) | |
| Location | 0.516 | ||
| Peripheral | 101 (74.3) | 7 (63.6) | |
| Central | 34 (25.0) | 4 (36.4) | |
| Unknown | 1 (0.7) | 0 (0.0) | |
| Lateral | 0.296 | ||
| Left | 66 (48.5) | 3 (27.3) | |
| Right | 70 (51.5) | 8 (72.7) | |
| pT stage | 0.072 | ||
| T1 | 78 (57.4) | 3 (27.3) | |
| T2 | 41 (30.1) | 5 (45.5) | |
| T3 | 15 (11.0) | 2 (18.2) | |
| T4 | 2 (1.5) | 1 (9.0) | |
| pN stage | 0.690 | ||
| N1 | 52 (38.2) | 3 (27.3) | |
| N2 | 84 (61.8) | 8 (72.7) | |
| Pathology | 1.000 | ||
| Adenocarcinoma | 128 (94.1) | 11 (100.0) | |
| Squamous cell carcinoma | 4 (3.0) | 0 (0.0) | |
| Adenosquamous carcinoma | 3 (2.2) | 0 (0.0) | |
| Sarcomatoid carcinoma | 1 (0.7) | 0 (0.0) | |
| Histological differentiation | 0.524 | ||
| Moderate-well | 18 (13.2) | 0 (0.0) | |
| Poor | 110 (80.9) | 11 (100.0) | |
| Unknown | 8 (5.9) | 0 (0.0) | |
| Radiotherapy | 0.086 | ||
| Yes | 39 (28.7) | 0 (0.0) | |
| No | 97 (71.3) | 11 (100.0) | |
| STAS | 0.021 | ||
| Yes | 82 (60.3) | 11 (100.0) | |
| No | 54 (39.7) | 0 (0.0) | |
| Vascular invasion | 0.094 | ||
| Yes | 26 (19.1) | 5 (45.5) | |
| No | 110 (80.9) | 6 (54.5) | |
| Operative procedure | 0.732 | ||
| Segmentectomy | 5 (3.7) | 1 (9.1) | |
| Lobectomy | 121 (89.0) | 10 (90.9) | |
| Sleeve resection | 6 (4.4) | 0 (0.0) | |
| Pneumectomy | 4 (2.9) | 0 (0.0) | |
| Medication duration | 4.0 [4.0–4.0] | 25.0 [16.5–28.0] | – |
| Side effects | 0.184 | ||
| Myelosuppression | 10 (7.4) | 0 (0.0) | |
| Liver injury | 8 (5.8) | 1 (9.1) | |
| Digestive symptom | 16 (11.8) | 2 (18.2) | |
| Myelosuppression + liver injury | 3 (2.2) | 0 (0.0) | |
| Myelosuppression + digestive symptom | 1 (0.7) | 0 (0.0) | |
| Liver injury + digestive symptom | 0 (0.0) | 1 (9.1) | |
| None or missing | 98 (72.1) | 7 (63.6) | |
| Recurrence location | 0.294 | ||
| Local | 30 (22.1) | 2 (18.2) | |
| Distant | 26 (19.1) | 0 (0.0) | |
| None or missing | 80 (58.8) | 9 (81.8) |
Values are mean ± SD, median [IQR] or n (%). NSCLC, non-small cell lung cancer; ALK-TKI, anaplastic lymphoma kinase-tyrosine kinase inhibitor; ECOG PS, Eastern Corporative Oncology Group Performance Status; pT stage, pathological T stage; pN stage, pathological N stage; STAS, spread through air space; Medication duration: chemotherapy in cycles, ALK-TKI in months; SD, standard deviation; IQR, interquartile range.